Pathologic Diagnosis of Mantle Cell Lymphoma

Clinical Lymphoma

Volumn 1, Issue 3, 2000, Pages 197-206

  Lai, Raymond ^a   Medeiros, L Jeffrey ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cyclin D1; Mantle cell lymphoma; Molecular diagnosis; Pathology; t(11; 14)(q13; q32)

Indexed keywords

CYTOGENETICS; GENETICS; HUMAN; MANTLE CELL LYMPHOMA; METHODOLOGY; PATHOLOGY; REVIEW;

CYTOGENETICS; HUMANS; LYMPHOMA, MANTLE-CELL;

EID: 0034574057     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.016     Document Type: Review

References (86)

1. Lennert K. Pathologie der Haslymphknoten: ein Abriss fuer Pathologen, Kliniker, praktizierende Aertae. New York, NY: Springer-Verlag, 1964.
2. Berard CW, Dorfman. Histopathology of malignant lymphomas. Clin Hematol 1974; 3:39-76.
3. Rappaport H, Winter WI, Hicks EB. Follicular lymphoma: a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956; 9:792-821.
4. Weisenburger DD, Nathwani BN, Diamond LW, et al. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer 1981; 48:1415-1425.
5. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer 1982; 49:1429-1438.
6. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112-2135.
7. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16:637-640.
8. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
9. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
10. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82:567-575.
11. Oinonen R, Franssila K, Teerenhovi L, et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998; 34:329-336.
12. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12:1281-1287.
13. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64:190-196.
14. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780-2795.
15. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89:2067-2078.
16. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6:257-262.
17. Bookman MA, Lardelli P, Jaffe ES, et al. Lymphocytic lymphoma of Intermediate differentiation: morphologic, immunophenotypic, and prognostic factors. J Natl Cancer Inst 1990; 82:742-743.
18. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and highdose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16:3803-3809.
19. Majlis A, Pugh WC, Rodriguez MA, et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997; 15:1664-1671.
20. Pittaluga S, Wlodarska I, Stul MS, et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology 1995; 26:17-24.
21. Weisenburger DD, Duggan MJ, Perry DA, et al. Non-Hodgkin's lymphomas of mantle zone origin. Pathol Annu 1991; 26:139-158.
22. Medeiros LJ, Jaffe ES. Low-grade B-cell lymphomas not specified in the Working Formulation. In: Jaffe ES, ed. Surgical Pathology of the Lymph Nodes and Related Organs. Second Edition, Major Problems in Pathology Series No. 16. Philadelphia: W.B. Saunders, 1995:221-233.
23. Piris MA, Mollejo M, Campo E, et al. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma. Histopathology 1998; 33:230-239.
24. Mollejo M, Lloret E, Solares J, et al. Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma. Am J Hematol 1999; 62:242-246.
25. Hashimoto Y, Nakamura N, Kuze T, et al. Multiple lymphomatous polyposis of the gastrointestinal tract is a heterogenous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of immunoglobulin heavy chain gene variable region. Hum Pathol 1999; 30:581-587.
26. Ruskone-Fourmestraux A, Delmer A, Lavergne A, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'etude des Lymphomes Digestifs. Gastroenterology 1997; 112:7-16.
27. O'Briain DS, Kennedy MJ, Daly PA, et al. Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type. Am J Surg Pathol 1989; 13:691-699.
28. Cornes J. Multiple lymphomatous polyposis of the gastrointestinal tract. Cancer 1961; 14:249-257.
29. Aguilera NS, Uusafr M, Wenig BM, et al. The blastic variant of mantle cell lymphoma arising in Waldeyer's tonsillar ring. J Laryngol Otol 1998; 112:991-994.
30. Pittaluga S, Verhoef G, Criel A, et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 1996; 21:115-125.
31. Criel A, Pittaluga S, Verhoef G, et al. Small B cell NHL and their leukemic counterpart: differences in subtyping and assessment of leukemic spread. Leukemia 1996; 10:848-853.
32. Wasman J, Rosenthal NS, Farhi DC. Mantle cell lymphoma. Morphologic findings in bone marrow involvement. Am J Clin Pathol 1996; 106:196-200.
33. Vasef MA, Medeiros LJ, Koo C, et al. Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol 1997; 108:302-307.
34. Cohen PL, Kurtin PJ, Donovan KA, et al. Bone marrow and peripheral blood involvement in mande cell lymphoma. Br J Haematol 1998; 101: 302-310.
35. Henrique R, Achten R, Maes B, et al. Guidelines for subtyping small B-cell lymphomas in bone marrow biopsies. Virchows Arch 1999; 435: 549-558.
36. Wong KF, Chan JK, So JC, et al. Mantle cell lymphoma in leukemic phase: characterization of its broad cytologic spectrum with emphasis on the importance of distinction from other chronic lymphoproliferative disorders. Cancer 1999; 86:850-857.
37. Singleton TP, Anderson MM, Ross CW, et al. Leukemic phase of mantle cell lymphoma, blastoid variant. Am J Clin Pathol 1999; 111:495-500.
38. Viswanatha DS, Foucar K, Berry BR, et al. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol 2000; 13:825-833.
39. Schlette E, Bueso-Ramos C, Giles F, et al. Mature B-cell leukemias with > 55% prolymphocytes: a group that includes an unusual variant of mantle cell lymphoma as well as de novo prolymphocytic leukemia and transformed chronic lymphocytic leukemia. Am J Clin Pathol 2000; 114:In Press.
40. Bedotto J, Spier CM, paquin ML, et al. Mantle zone lymphoma with central nervous system involvement. Cancer 1986; 58:2125-2129.
41. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14:941-944.
42. Swerdlow SH, Zukerberg LR, Yang WI, et al. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements. Am J Surg Pathol 1996; 20:627-640.
43. Tsang P, Pan L, Cesarman E, et al. A distinctive composite lymphoma consisting of clonally related mantle cell lymphoma and follicle center cell lymphoma. Hum Pathol 1999; 30:988-992.
44. Fend F, Quintanilla-Martinez L, Kumar S, et al. Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection. Am J Pathol 1999; 154:1857-1866.
45. Cachia AR, Diss TC, Isaacson PG. Composite mantle-cell lymphoma and plasmacytoma. Hum Pathol 1997; 28:1291-1295.
46. Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation duster region and tetraploid chromosome clones. Blood 1997; 89:1421-1429.
47. Norton AJ, Matthews J, Pappa V, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995; 6:249-256.
48. Kaleem Z, Wakoff AR, Smith RP, et al. Blastic transformation of mantle cell lymphoma. Arch Pathol Lab Med 1996; 120:577-580.
49. Tamaru J, Kawana H,Takahashi Y, et al. Expression of cell cycle regulating proteins in an unusual transformation of mantle cell lymphoma. Leuk Lymphoma 1999; 36:129-137.
50. Motokura T, Arnold A, PRAD1/cydin D1 proto-oncogene: genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer 1993; 7:89-95.
51. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79:573-582.
52. Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene 1997; 14:1191-1200.
53. Lai R, Medeiros LJ, Coupland R, et al. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11:457-463.
54. Bodrug SE, Warner BJ, Bath ML, et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. Embo J 1994; 13:2124-2130.
55. Lovec H, Grzeschiczek A, Kowalski MB. et al. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. Embo J 1994; 13:3487-3495.
56. Cuneo A, Bigoni R, Rigolin GM, et al. Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features. Blood 1999; 93:1372-1380.
57. Stilgenbauer S, Winkler D, Ott G, et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 1999; 94:3262-3264.
58. Monni O, Zhu Y, Franssila K, et al. Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma. Br J Haematol 1999; 104:665-671.
59. Monni O, Oinonen R, Elonen E, et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 1998; 21:298-307.
60. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93:4365-4374.
61. Schaffner C, Idler I, Stilgenbauer S, et al. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97:2773-2778.
62. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89:272-280.
63. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87:4302-4310.
64. Zoldan MC, Inghirami G, Masuda Y, et al. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996; 93:475-486.
65. Williams ME, Whitefield M, Swerdlow SH. Analysis of the cyclindependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol 1997;8 (suppl 2):71-73.
66. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998; 153:175-182.
67. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619-626.
68. Molot RJ, Meeker TC, Wittwer CT, et al. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas. Blood 1994; 83:1626-1631.
69. Zukerberg LR, Medeiros LJ, Ferry JA, et al. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993; 100:373-385.
70. Su W, Yeong KF, Spencer J. Immunohistochemical analysis of human CD5 positive B cells: mantle cells and mantle cell lymphoma are not equivalent in terms of CD5 expression. J Clin Pathol 2000; 53:395-397.
71. Vasef MA, Medeiros LJ. Yospur LS, et al. Cydin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997; 10:927-932.
72. Zukerberg LR, Yang WI, Arnold A, et al. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 1995; 103:756-760.
73. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000; 95:2253-2261.
74. Hoffman DG, Tucker SJ, Emmanoulides C, et al. CD8-positive mantle cell lymphoma: a report of two cases. Am J Clin Pathol 1998; 109:689-694.
75. McCarron KF, Hammel JP, Hsi ED. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders. Am J Clin Pathol 2000; 113:805-813.
76. Strickler JG, Medeiros LJ, Copenhaver CM, et al. Intermediate lymphocytic lymphoma: an immunophenotypic study with comparison to small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Hum Pathol 1988; 19:550-554.
77. Estalilla O, Luthra R, Lee M, et al. Real-time quantitative RT-PCR assay for cyclin D1 expression in mantle cell lymphoma and other non-Hodgkin's lymphomas. Mod Pathol 2000; 13:148A.
78. Wlodarska I, Pittaluga S, Hagemeijer A, et al. Secondary chromosome changes in mantle cell lymphoma. Haematologica 1999; 84:594-599.
79. Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994; 83:1871-1875.
80. Medeiros LJ, Van Krieken JH, Jaffe ES, et al. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990; 76:2086-2090.
81. de Boer CJ, Loyson S, Kluin PM, et al. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res 1993: 53:4148-4152.
82. Williams ME, Swerdlow SH, Rosenberg CL, et al. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992; 52:5541s-5544s.
83. Vaandrager JW, Schuuring E, Zwikstra E, et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 1996: 88:1177-1182.
84. Siebert R, Matthiesen P, Harder S, et al. Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol 1998; 9:519-526.
85. Remstein ED, Kurtin PJ, Buno I, et al. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000; 110: 856-862.
86. Katz RL, Caraway NP, Gu J, et al. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol 2000; 114:248-257.